Thermo Fisher beats profit, revenue expectations in Q3

Investing.com -- Thermo Fisher Scientific on Wednesday reported third-quarter profit and revenue above analyst estimates.

Earnings per share were $6.68, ahead of the $6.40 analysts expected, while revenue came in at $12.14 billion, versus the $11.95 billion consensus. Revenue grew 9%, including organic growth of 6%.

Adjusted operating income rose 15% to $2.97 billion, and the adjusted operating margin widened to 24.5% from 23.3% a year earlier, above the 24% estimate.

“We are very pleased to deliver another excellent quarter, with outstanding financial performance on both the top and bottom line,” said Marc Casper, chairman and chief executive officer of Thermo Fisher Scientific. “We’re advancing our proven growth strategy, which is resonating strongly with our customers, and our PPI Business System is enabling outstanding execution across the company.”

Results were mixed by segment. Laboratory products and services was the biggest contributor, with revenue up 15% to $6.86 billion, above the $6.56 billion estimate. Analytical instruments grew 5.8% to $2.00 billion, also ahead of expectations.

Life sciences solutions grew 5.1% to $2.72 billion, below the $2.84 billion estimate, and specialty diagnostics fell 6.5% to $1.10 billion, below the $1.16 billion estimate.

Thermo said it will provide updated 2026 financial guidance on its earnings call at 7 am ET.

Original Article

You May Also Be Interested In

• Tesla stock up as automotive gross margin improves, free cash flow turns positive
• Rollins falls 7% on third quarter earnings and revenue miss
• SAP shares climb after Q3 earnings beat and strong cloud revenue outlook